



THE
BLADDER CANCER
COMPANY™

Photocure ASA: Presentation of the third quarter 2018 results

Photocure will present its third quarter report on Thursday 8 November 2018 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).

Representatives from the company will be Daniel Schneider, CEO, Erik Dahl, CFO and Ambaw Bellete, President, Photocure Inc. and Head, US Cancer Commercial Operations. Jan Egberts, Chairperson of Photocure ASA, will also be present. The presentation will be held in English.

The quarterly report and presentation will be published at 07:00 CET and will be publicly available at www.photocure.com. It will be possible to follow the presentation through <http://webtv.hegnar.no/presentation.php?webcastId=97451491>.

A light snack will be served from 08:00 (CET). The presentation is scheduled to conclude at 09:15 (CET).

Please register your attendance to the presentations at Photocure by Wednesday 7 November.

Contact person: Tolv Hillestad (e-mail: th@photocure.no / phone +47 22 06 22 10).

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Erik Dahl, CFO
Tel: +47 450 55 000
Email: ed@photocure.no

About Photocure ASA

Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). The US headquarters for Photocure Inc., are in Princeton, New Jersey. For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com